Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T13:42:14.945Z.
Calculation as of: 2026-10-06T13:42:14.945Z.
Quote observation: 2026-10-06T13:40:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: df0d51bc4c7c4fe031789de0e9442acf829cec50a05ec95901a80cda74a8a9f3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$3.11B
PS Ratio
862.69
TTM Avg
1171.95
3Y Avg
915.38
5Y Avg
373.66
Market Cap
$3.12B
PS Ratio
6.72
TTM Avg
9.18
3Y Avg
9.54
5Y Avg
123.98
Market Cap
$3.08B
PS Ratio
N/A
TTM Avg
1.30
3Y Avg
815.49
5Y Avg
815.49
Market Cap
$3.58B
PS Ratio
15.30
TTM Avg
44.87
3Y Avg
169.56
5Y Avg
109.21
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.19B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.11B | 862.69 | 1171.95 | 915.38 | 373.66 |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.12B | 6.72 | 9.18 | 9.54 | 123.98 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.08B | N/A | 1.30 | 815.49 | 815.49 |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.42B | 3.00 | 3.85 | 3.95 | 5.00 |
| TransMedics Group, Inc. (TMDX)vs › | $2.89B | 4.33 | 7.07 | 9.70 | 14.76 |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 5.04 | 3.27 | 3.39 | 5.20 |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.86B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.58B | 15.30 | 44.87 | 169.56 | 109.21 |
| Celcuity Inc. (CELC)vs › | $3.56B | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-03 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
